# US 2020/0392500 A1 · Aav-based treatment of cholesterol-related disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0392500 A1
- Document ID: US20200392500A1
- Status: Published application
- Kind: A1
- Application number: 16/908,798
- Filed: 2020-06-23
- Published: 2020-12-17
- Earliest claimed: 2010-04-23
- Assignees: University of Massachusetts
- Applicants: University of Massachusetts
- Inventors: Guangping Gao; Phillip D. Zamore; Jun Xie
- Web page: https://patentgrep.com/patent/US20200392500A1

## CPC

- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61P 1/14: Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/06: Antihyperlipidemics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 5/00: Drugs for disorders of the endocrine system
- A61P 5/18: of the parathyroid hormones
- A61P 13/12: of the kidneys
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/20: Hypnotics; Sedatives
- A61P 31/12: Antivirals
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- C12N 15/86: Viral vectors
- C12Q 1/68: involving nucleic acids
- C12Q 1/6897: involving reporter genes operably linked to promoters
- C12N 2310/113: targeting other non-coding nucleic acids, e.g. antagomirs
- C12N 2310/531: Stem-loop; Hairpin
- C12N 2320/32: Special delivery means, e.g. tissue-specific
- C12N 2330/51: Specially adapted vectors
- C12N 2750/14143: viral genome or elements thereof as genetic vector
- C12N 2750/14171: Demonstrated in vivo effect
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

The invention in some aspects relates to methods and compositions for assessing the effectiveness of miRNA inhibitors. In other aspects of the invention, methods and compositions for treating cholesterol related disorders are provided. In one aspect of the invention, miRNA inhibitors against miR-122 and rAAV-based compositions comprising the same are provided.

## Claims

### Claim at position 1

-56. (canceled)

### Claim 57

A miRNA inhibitor comprising:
a first miRNA binding site and a second miRNA binding site, wherein a first stem sequence flanks the first miRNA binding site at its 5′-end, a second stem sequence flanks the first miRNA binding site at its 3′-end and the second miRNA binding site at its 5′-end, and a third stem sequence flanks the second miRNA binding site at its 3′-end, wherein at least one of the miRNA binding sites comprises a nucleotide sequence complementary to a consensus sequence of the plurality of target miRNAs.

### Claim 58 (depends on 57)

The miRNA inhibitor of claim 57, wherein each of the two miRNA inhibitor binding sites comprises a non-binding, central portion that is not complementary with any of the plurality of miRNAs targeted by the miRNA inhibitor.

### Claim 59 (depends on 58)

The miRNA inhibitor of claim 58, wherein the non-binding, central portion of the first miRNA binding site is at least partially complementary with the non-binding, central portion of the second miRNA binding site.

### Claim 60 (depends on 58)

The miRNA inhibitor of claim 58, wherein the non-binding, central portion of the first miRNA binding site is complementary with the non-binding, central portion of the second miRNA binding site at 1 to 5 nucleotides.

### Claim 61 (depends on 58)

The miRNA inhibitor of claim 58, wherein the non-binding, central portion of the first miRNA binding site is complementary with the non-binding, central portion of the second miRNA binding site at 3 nucleotides.

### Claim 62 (depends on 58)

The miRNA inhibitor of claim 58, wherein the non-binding, central portion of the first miRNA binding site and/or second miRNA binding site has a length in a range of 1 to 10 nucleotides.

### Claim at position 8

-67. (canceled)

### Claim 68 (depends on 57)

The miRNA inhibitor of claim 57, wherein the first miRNA binding site and the second miRNA binding site are complementary at a sequence of 2 to 10 nucleotides in length.

### Claim 69

(canceled)

### Claim 70 (depends on 57)

The miRNA inhibitor of claim 57, wherein the miRNA inhibitor comprises two or more miRNA binding sites.

### Claim 71 (depends on 57)

The miRNA inhibitor of claim 57, wherein the miRNA inhibitor is a TuD.

### Claim 72 (depends on 57)

The miRNA inhibitor of claim 57, wherein the miRNA inhibitor targets a plurality of let-7 family members.

### Claim 73 (depends on 71)

The miRNA inhibitor of claim 71, wherein the miRNA inhibitor comprises a sequence of at least 8 contiguous nucleotides of SEQ ID NO: 18.

### Claim 74 (depends on 73)

The miRNA inhibitor of claim 73, wherein the miRNA inhibitor comprises the first ten nucleotides and/or the last ten nucleotides of SEQ ID NO: 18.

### Claim 75 (depends on 57)

The miRNA inhibitor of claim 57, wherein the miRNA inhibitor comprises [r consists of the nucleotide sequence of SEQ ID NO: 18 or SEQ ID NO: 20.

### Claim 76

A method, comprising
obtaining a consensus sequence from a plurality of miRNAs, and
generating a miRNA inhibitor targeting a plurality of miRNAs, wherein the miRNA inhibitor comprises a first miRNA binding site and a second miRNA binding site, wherein a first stem sequence flanks the first miRNA binding site at its 5′-end, a second stem sequence flanks the first miRNA binding site at its 3′-end and the second miRNA binding site at its 5′-end, and a third stem sequence flanks the second miRNA binding site at its 3′-end, wherein the miRNA inhibitor comprises a nucleotide sequence complementary to the consensus sequence of the plurality 5 of target miRNAs.

### Claim at position 18

-78. (canceled)

### Claim 79

A miRNA inhibitor comprising a nucleotide sequence of SEQ ID NO: 22, or SEQ ID NO: 24.

### Claim 80 (depends on 57)

A method comprising contacting a cell with an miRNA inhibitor of claim 57.

### Claim 81 (depends on 57)

The miRNA inhibitor of claim 57, wherein at least one of the miRNA binding sites comprises a sequence as set forth in SEQ ID NO: 1, SEQ ID NO: 5, SEQ ID NO: 21, or SEQ ID NO: 23.

### Claim 82 (depends on 57)

The miRNA inhibitor of claim 57, wherein the miRNA inhibitor targets miR-122.

### Claim 83 (depends on 57)

A recombinant Adeno-Associated Virus (rAAV) comprising at least one transgene that expresses the miRNA inhibitor of claim 57.

### Claim 84 (depends on 83)

The rAAV of claim 83, wherein the rAAV has a capsid of the AAV9 serotype variant, Csp-3, which has a sequence as set forth in SEQ ID NO: 4.
